Abstract:Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection is associated with a clear prothrombotic phenotype. Although the exact pathophysiological mechanisms are not yet fully understood, thrombosis is clearly a highly important in the prognosis and outcome of COVID-19. As such, there is a need for diagnostic analysis and quantification of the coagulation potential in these patients, both at diagnosis and follow-up. Global coagulation assays like thrombin generation (TG) and rotational thromboelastometry (ROTEM) might be suitable in estimating COVID-19 associated coagulopathy and thrombosis risk. Therefore, we aimed at validating both assays for samples with high levels of fibrinogen and in the presence of anticoagulant heparins, such as commonly observed for COVID-19 ICU patients. Materials and methods: Calibrated Automated Thrombography (CAT) was optimized to assess plasma thrombin generation in the presence of heparins. The final conditions with either 10 μg/mL Ellagic acid (EA) or PPP Reagent HIGH (high tissue factor; HPPH) were validated according to the EP5 protocol for within-run and between-run variability. Overall variability was well below 10%. To estimate the influences of heparins and high fibrinogen levels, CAT was performed on spiked plasma aliquots from 13 healthy volunteers. Comparable to the CAT method, tPA-ROTEM was used to validate the effect of high fibrinogen and heparins on clotting time, clot firmness and clot lysis parameters. Results: Our adjusted COVID-19 assay showed a heparin dose dependent decrease in peak height and endogenous thrombin potential (ETP) for both EA and HPPH triggered variants. High fibrinogen did not alter the inhibitory effect of either LMWH or UFH, nor did it influence the peak height or ETP in any of the conditions. The tPA-ROTEM showed a significant prolongation in clotting time with the additions of heparin, which normalized with the addition of high fibrinogen. MCF was markedly increased in all hyperfibrinogenemic conditions. A trend towards increased lysis time and, thus, decreased fibrinolysis was observed. Conclusion: Thrombin generation and tPA-ROTEM protocols for measurements in the COVID-19 populations were adjusted and validated. The adjusted thrombin generation assay shows good sensitivity for measurements in heparin spiked plasma. High levels of fibrinogen did not alter the assay or the effectiveness of heparins as measured in this assay. t-PA ROTEM was effective in measurement of both high fibrinogen and heparins spiked samples and was sensitive to the expected relevant coagulant changes by these conditions. No clear fibrinolytic effect was observed in different conditions.

Investigation of thrombin concentration at the time of clot formation in simultaneous thrombin and fibrin generation assays

Measurement of tissue factor activity in whole blood

Thrombodynamics, a new global coagulation test: Measurement of heparin efficiency

Comprehensive Analysis of the Role of Fibrinogen and Thrombin in Clot Formation and Structure for Plasma and Purified Fibrinogen

Thrombin generation assays are versatile tools in blood coagulation analysis: A review of technical features, and applications from research to laboratory routine

Plasma levels of complement components C5 and C9 are associated with thrombin generation

Development and validation of an in vitro model to study thrombin generation on the surface of catheters in platelet-poor and platelet-rich plasma

Suggestions for global coagulation assays for the assessment of COVID-19 associated hypercoagulability

New Insights into How Blood Clots: Implications for the Use of APTT and PT as Coagulation Screening Tests and in Monitoring of Anticoagulant Therapy

Low thrombin generation predicts poor prognosis in ischemic stroke patients after thrombolysis

Laboratory Testing for Fibrinogen Disorders: From Routine Investigations to Research Studies

The effect of factor XIa on thrombin and plasmin generation, clot formation, lysis and density in coagulation factors deficiencies

A specific fluorescence resonance energy quenching-based biosensor for measuring thrombin activity in whole blood

Endogenous Thrombin Potential and Time-Dependent Thrombin Generation Parameters are Independent Risk Factors for Mortality in the General Population

Analysis of fibrin networks using topological data analysis – a feasibility study

Evaluation of thrombomodulin/thrombin activatable fibrinolysis inhibitor function in plasma using tissue-type plasminogen activator-induced plasma clot lysis time

Microrheology and structural quantification of hypercoagulable clots

[Factors influencing thrombin generation measured as thrombin-antithrombin complexes levels and using calibrated automated thrombogram in patients with advanced coronary artery disease]

Abstract WP152: Changes In Thrombus Fibrin Content By Time In Patients Undergoing Thrombectomy

Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A

Performance Evaluation Of Thrombomodulin, Thrombin-Antithrombin Complex, Plasmin-Alpha 2-Antiplasmin Complex, And T-Pa: Pai-1 Complex